Kidney CancerPhase 3NCT00072046
Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer)
A Phase 3 study testing bevacizumab and recombinant interferon alfa in people with Kidney Cancer, run by Alliance for Clinical Trials in Oncology at 493 sites in 2 countries.
Trial summary
RATIONALE: Biological therapies, such as interferon alfa-2b, may interfere with the growth of tumor cells. Bevacizumab may stop the growth of tumor cells by stopping blood flow to the tumor. Read more about this study
- Who is it for?
- Ages 18 to 120 years
- Conditions the study is for
- Kidney Cancer
- What is being tested?
- bevacizumab and recombinant interferon alfa
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 732 participants
- Where
- 493 sitesin 2 countries
- Study dates
- Oct 2003to Nov 2012
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 120 years
- All sexes
- No healthy volunteers
- Adult, Older adult
DISEASE CHARACTERISTICS:
- Histologically or cytologically confirmed renal cell carcinoma (RCC)
- Conventional clear cell carcinoma
- Metastatic or unresectable disease
- The following characteristics and cellular types are excluded:
- True papillary
- Sarcomatoid features without a clear cell component
- Chromophobe
- Oncocytoma
- Collecting duct tumor
- Transitional cell carcinoma
- Measurable or nonmeasurable disease, including any of the following:
- Unidimensionally measurable lesion ≥ 20 mm by conventional techniques (e.g., physical exam or chest x-ray) OR 10 mm by spiral CT scan or MRI
- The following are considered nonmeasurable disease:
- Small lesions
- Bone lesions
- Leptomeningeal disease
- Ascites
- Pleural/pericardial effusion
- Lymphangitis cutis/pulmonis
- Abdominal masses that are not confirmed and followed by imaging techniques
- Cystic lesions
- Irradiated lesions, unless progression is documented after radiotherapy
- RCC paraffin tissue blocks or unstained slides must be available
- No evidence of prior or concurrent CNS metastases by MRI or CT scan
PATIENT CHARACTERISTICS:
Age
- 18 and over
Performance status
- Karnofsky 70-100%
Life expectancy
- Not specified
Hematopoietic
- Granulocyte count ≥ 1,500/mm^3
- Platelet count ≥ 100,000/mm^3
- No history of clinically significant bleeding
Hepatic
- AST/ALT ≤ 2.5 times upper limit of normal (ULN)
- Alkaline phosphatase ≤ 2.5 times ULN
- Bilirubin ≤ 1.5 times ULN
Renal
- Creatinine ≤ 1.5 times ULN
- No proteinuria > 1+
- Proteinuria ≥ 2+ allowed provided protein is < 2 g/24-hour urine collection
Cardiovascular
- No deep venous thrombosis within the past year
- No cerebrovascular accident within the past year
- No peripheral vascular disease with claudication on < 1 block
- No uncontrolled hypertension defined as blood pressure ≥160 mm Hg (systolic) and/or ≥ 90 mm Hg (diastolic) while on medication
- No New York Heart Association class II-IV congestive heart failure
- No angina pectoris requiring nitrate therapy
- No myocardial infarction within the past 6 months
- No other significant cardiovascular disease
Pulmonary
- No pulmonary embolus within the past year
- No ongoing hemoptysis
Other
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 3 months after study treatment
- No preexisting thyroid abnormality in which normal thyroid function cannot be maintained by medication
- No delayed wound healing, ulcers, or bone fractures
- No uncontrolled psychiatric disorder
- No other currently active* malignancy except nonmelanoma skin cancer NOTE: *Disease is not considered currently active if patient completed anticancer therapy and is considered to have < 30% risk of relapse
PRIOR CONCURRENT THERAPY:
Biologic therapy
- No prior systemic immunotherapy for RCC
- No prior thalidomide, anti-vascular endothelial growth factor (VEGF) therapy, VEGF receptor inhibitors, or antiangiogenic treatment of any kind
- No concurrent prophylactic filgrastim (G-CSF) or sargramostim (GM-CSF)
Chemotherapy
- No prior systemic chemotherapy for RCC
- No concurrent chemotherapy
Endocrine therapy
- No concurrent systemic corticosteroid therapy except the following:
- Topical and inhaled steroids
- Replacement therapy for adrenal insufficiency
- No concurrent hormones except those administered for nondisease-related conditions (e.g., insulin for diabetes)
Radiotherapy
- See Disease Characteristics
- At least 4 weeks since prior radiotherapy and recovered
- Prior palliative radiotherapy to metastatic lesions allowed provided at least 1 measurable or nonmeasurable lesion remains untreated
- No concurrent palliative radiotherapy
Surgery
- At least 4 weeks since prior major surgery and recovered
Other
- No other prior systemic investigational therapy for RCC
- No other prior adjuvant or neoadjuvant systemic therapy for RCC
- No concurrent full-dose oral or parenteral anticoagulation* NOTE: *Low-dose (1 mg) warfarin for maintenance of catheter patency and/or daily prophylactic aspirin is allowed
Trial locations and contacts
493 sites in 2 countries.
304 sites in 2 countries
United States300 sites
Kapiolani Medical Center at Pali Momi
‘Aiea, Hawaii, 96701
Abington Memorial Hospital
Abington, Pennsylvania, 19001
Hickman Cancer Center at Bixby Medical Center
Adrian, Michigan, 49221
Akron City Hospital at Summa Health System
Akron, Ohio, 44304
Phoebe Cancer Center at Phoebe Putney Memorial Hospital
Albany, Georgia, 31703
Hematology-Oncology Associates, PC
Albuquerque, New Mexico, 87106
University of New Mexico Cancer Research and Treatment Center
Albuquerque, New Mexico, 87106
Lovelace Medical Center at Lovelace Sandia Health System
Albuquerque, New Mexico, 87108
Veterans Affairs Medical Center - Albuquerque
Albuquerque, New Mexico, 87108
John and Dorothy Morgan Cancer Center at Lehigh Valley Hospital
Allentown, Pennsylvania, 18105
Emory University Hospital - Atlanta
Altanta, Georgia, 30322
Saint Anthony's Hospital at Saint Anthony's Health Center
Alton, Illinois, 62002
McFarland Clinic, P.C.
Ames, Iowa, 50010
Rose Ramer Cancer Clinic at Anderson Area Medical Center
Anderson, South Carolina, 29621
CCOP - Michigan Cancer Research Consortium
Ann Arbor, Michigan, 48100
St. Joseph Mercy Cancer Center at St. Joseph Mercy Hospital
Ann Arbor, Michigan, 48106-0995
Fox Valley Hematology and Oncology
Appleton, Wisconsin, 54911-3496
Arlington Cancer Center - Arlington
Arlington, Texas, 76012
Arroyo Grande Community Hospital
Arroyo Grande, California, 93420
Randolph Hospital
Asheboro, North Carolina, 27203
Mission Hospitals - Memorial Campus
Asheville, North Carolina, 28801
Hematology and Oncology of Northeast Georgia
Athens, Georgia, 30607
Piedmont Hospital
Atlanta, Georgia, 30309
CCOP - Atlanta Regional
Atlanta, Georgia, 30342
Northside Hospital Cancer Center
Atlanta, Georgia, 30342
Saint Joseph's Hospital of Atlanta
Atlanta, Georgia, 30342
Augusta Oncology Associates
Augusta, Georgia, 30901
MBCCOP-Medical College of Georgia Cancer Center
Augusta, Georgia, 30912
Aurora Presbyterian Hospital
Aurora, Colorado, 80012
Rush-Copley Cancer Care Center
Aurora, Illinois, 60507
WellStar Cobb Hospital
Austell, Georgia, 30106
Greenebaum Cancer Center at University of Maryland Medical Center
Baltimore, Maryland, 21201-1595
St. Agnes Cancer Center
Baltimore, Maryland, 21229
CancerCare of Maine at Eastern Maine Medial Center
Bangor, Maine, 04401
Baton Rouge General Regional Cancer Center
Baton Rouge, Louisiana, 70806
Mary Bird Perkins Cancer Center - Baton Rouge
Baton Rouge, Louisiana, 70809
Ochsner Clinic of Baton Rouge
Baton Rouge, Louisiana, 708169990
Battle Creek Health System
Battle Creek, Michigan, 49017
St. Francis Hospital and Health Centers
Beech Grove, Indiana, 46107
MeritCare Clinic - Bemidji
Bemidji, Minnesota, 56601
Mountainview Medical
Berlin Corners, Vermont, 05602
St. Luke's Hospital Cancer Center
Bethlehem, Pennsylvania, 18015
Hematology Oncology Associates of the Quad Cities
Bettendorf, Iowa, 52722
Mecosta County General Hospital
Big Rapids, Michigan, 49307
CCOP - Montana Cancer Consortium
Billings, Montana, 59101
Comprehensive Cancer Center at University of Alabama at Birmingham
Birmingham, Alabama, 35294
Bismarck Cancer Center
Bismarck, North Dakota, 58501
Medcenter One Health System
Bismarck, North Dakota, 58501
Mid Dakota Clinic, P.C.
Bismarck, North Dakota, 58501
St. Joseph Medical Center
Bloomington, Illinois, 61701
St. Elizabeth Boardman Cancer Center
Boardman, Ohio, 44512
Lynn Regional Cancer Center of Boca Raton Community Hospital
Boca Raton, Florida, 33486
Mountain States Tumor Institute - Boise
Boise, Idaho, 83712
Cancer Center at Tufts - New England Medical Center
Boston, Massachusetts, 02111
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215
Boulder Community Hospital
Boulder, Colorado, 80301
Wood County Oncology Center
Bowling Green, Ohio, 43402
Brainerd Medical Center
Brainerd, Minnesota, 56401
Roswell Park Cancer Institute
Buffalo, New York, 14263
Lahey Clinic Medical Center - Burlington
Burlington, Massachusetts, 01805
Fletcher Allen Health Care - University Health Center Campus
Burlington, Vermont, 05401
Fairview Ridges Hospital
Burnsville, Minnesota, 55337
Cancer Institute of New Jersey at the Cooper University Hospital
Camden, New Jersey, 08103
Graham Hospital
Canton, Illinois, 61520
University Hospitals Ireland Cancer Center at Mercy Medical Center
Canton, Ohio, 44708
Aultman Hospital Cancer Center at Aultman Health Foundation
Canton, Ohio, 44710
Southeast Missouri Regional Cancer Center at Southeast Missouri Hospital
Cape Girardeau, Missouri, 63701
St. Francis Medical Center
Cape Girardeau, Missouri, 63701
Saint Anthony Regional Hospital
Carroll, Iowa, 51401
Memorial Hospital
Carthage, Illinois, 62321
Iowa Blood and Cancer Care
Cedar Rapids, Iowa, 52402
St. Luke's Hospital
Cedar Rapids, Iowa, 52402
Cedar Rapids Oncology Associates
Cedar Rapids, Iowa, 52403
Mercy Cancer Center at Mercy Medical Center
Cedar Rapids, Iowa, 52403
Cancer Center of Kansas - Chanute
Chanute, Kansas, 66720
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
Chapel Hill, North Carolina, 27599
West Virginia University - Robert C. Byrd Health Sciences Center - Charleston Division
Charleston, West Virginia, 25304
Presbyterian Cancer Center at Presbyterian Hospital
Charlotte, North Carolina, 28233
Cancer Center at the University of Virginia
Charlottesville, Virginia, 22908
Saint Luke's Hospital
Chesterfield, Missouri, 63017-3417
University of Illinois Medical Center
Chicago, Illinois, 60612
University of Chicago Cancer Research Center
Chicago, Illinois, 60637-1470
Adena Regional Medical Center
Chillicothe, Ohio, 54601
MetroHealth's Cancer Care Center at MetroHealth Medical Center
Cleveland, Ohio, 44109
Cancer Center of Colorado Springs
Colorado Springs, Colorado, 80907
Memorial Hospital Cancer Center
Colorado Springs, Colorado, 80909
Penrose Cancer Center at Penrose Hospital
Colorado Springs, Colorado, 80933
Missouri Cancer Associates
Columbia, Missouri, 65201
Ellis Fischel Cancer Center at University of Missouri - Columbia
Columbia, Missouri, 65203
South Carolina Oncology Associates
Columbia, South Carolina, 29210
John B. Amos Community Cancer Center
Columbus, Georgia, 31902
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University
Columbus, Ohio, 43210
Riverside Methodist Hospital Cancer Care
Columbus, Ohio, 43214
CCOP - Columbus
Columbus, Ohio, 43215
Grant Riverside Cancer Services
Columbus, Ohio, 43215
Mount Carmel West Hospital
Columbus, Ohio, 43222
Doctors Hospital at Ohio Health
Columbus, Ohio, 43228
Batte Cancer Center at Northeast Medical Center
Concord, North Carolina, 28025
Mercy Hospital
Coon Rapids, Minnesota, 55433
Louis Busch Hager Cancer Center at Mary Imogene Bassett Hospital
Cooperstown, New York, 13326
Alegent Health Mercy Hospital
Council Bluffs, Iowa, 51503
Medical City Dallas Hospital
Dallas, Texas, 75230
Simmons Cancer Center at University of Texas Southwestern Medical Center - Dallas
Dallas, Texas, 75390
Geisinger Medical Center
Danville, Pennsylvania, 17822-2001
Danville Regional Medical Center
Danville, Virginia, 24541
Genesis Regional Cancer Center at Genesis Medical Center
Davenport, Iowa, 52803
Grandview Hospital
Dayton, Ohio, 45405
Good Samaritan Hospital
Dayton, Ohio, 45406
Miami Valley Hospital
Dayton, Ohio, 45409
Samaritan North Cancer Care Center
Dayton, Ohio, 45415
Veterans Affairs Medical Center - Dayton
Dayton, Ohio, 45428
CCOP - Dayton
Dayton, Ohio, 45429
Halifax Medical Center
Daytona Beach, Florida, 32115
Charles B. Eberhart Cancer Center at DeKalb Medical Center
Decatur, Georgia, 30033
Veterans Affairs Medical Center - Atlanta (Decatur)
Decatur, Georgia, 30033
Decatur Memorial Hospital Cancer Care Institute
Decatur, Illinois, 62526
Grady Memorial Hospital
Delaware, Ohio, 43015
Porter Adventist Hospital
Denver, Colorado, 80210
Presbyterian - St. Luke's Medical Center
Denver, Colorado, 80218
St. Joseph Hospital
Denver, Colorado, 80218
Rose Medical Center
Denver, Colorado, 80220
CCOP - Colorado Cancer Research Program, Incorporated
Denver, Colorado, 80224-2522
Mercy Capitol Hospital
Des Moines, Iowa, 50307
CCOP - Iowa Oncology Research Association
Des Moines, Iowa, 50309
John Stoddard Cancer Center at Iowa Methodist Medical Center
Des Moines, Iowa, 50309
Medical Oncology and Hematology Associates at John Stoddard Cancer Center
Des Moines, Iowa, 50309
Medical Oncology and Hematology Associates at Mercy Cancer Center
Des Moines, Iowa, 50314
Mercy Cancer Center at Mercy Medical Center - Des Moines
Des Moines, Iowa, 50314
John Stoddard Cancer Center at Iowa Lutheran Hospital
Des Moines, Iowa, 50316
Cancer Center of Kansas - Dodge City
Dodge City, Kansas, 67801
Kent General Hospital at Bayhealth Medical Center
Dover, Delaware, 19901
City of Hope Comprehensive Cancer Center
Duarte, California, 91010
Oncology Hematology Associates of Northern Pennsylvania, P.C. at Hahne Regional Cancer Center
DuBois, Pennsylvania, 15801
Wendt Regional Cancer Center at Finley Hospital
Dubuque, Iowa, 52001
Cancer Care Center at St. Luke's Hospital
Duluth, Minnesota, 55802
Duke Comprehensive Cancer Center
Durham, North Carolina, 27710
Veterans Affairs Medical Center - East Orange
East Orange, New Jersey, 07018-1095
John Smith, Jr./Dalton McMichael Cancer Center at Morehead Memorial Hospital
Eden, North Carolina, 27288
Fairview Southdale Hospital
Edina, Minnesota, 55435
Cancer Center of Kansas, P.A. - El Dorado
El Dorado, Kansas, 67042
Alexian Brothers Cancer Care Center
Elk Grove Village, Illinois, 60007
Elkhart General Hospital
Elkhart, Indiana, 46515
Vince Lombardi Cancer Center - Elkhorn
Elkhorn, Wisconsin, 53121
Union Hospital Cancer Center at Union Hospital
Elkton MD, Maryland, 21921
Swedish Medical Center
Englewood, Colorado, 80110
Eureka Hospital
Eureka, Illinois, 61530
Evanston Northwestern Health Care - Evanston Hospital
Evanston, Illinois, 60201
Dakota Cancer Institute at Innovis Health - Dakota Clinic
Fargo, North Dakota, 58103
CCOP - MeritCare Hospital
Fargo, North Dakota, 58122
MeritCare Medical Group
Fargo, North Dakota, 58122
Blanchard Valley Medical Associates
Findlay, Ohio, 45840
Hunterdon Regional Cancer Center at Hunterdon Medical Center
Flemington, New Jersey, 08822
Genesys Hurley Cancer Institute
Flint, Michigan, 48532
Front Range Cancer Specialists
Fort Collins, Colorado, 80524
Poudre Valley Hospital
Fort Collins, Colorado, 80524
Michael & Dianne Bienes Comprehensive Cancer Center at Holy Cross Hospital
Fort Lauderdale, Florida, 33308
Hembree Mercy Cancer Center at St. Edward Mercy Medical Center
Fort Smith, Arkansas, 72903
Fort Wayne Medical Oncology and Hematology, Incorporated
Fort Wayne, Indiana, 46815
Kaiser Permanente - Fremont
Fremont, California, 94538
Fremont Area Medical Center
Fremont, Nebraska, 68025
Fremont Memorial Hospital
Fremont, Ohio, 43420
Mercy and Unity Cancer Center at Mercy and Unity Hospitals
Fridley, Minnesota, 55432
Shands Cancer Center at the University of Florida - Jacksonville
Gainesville, Florida, 32610
Northeast Georgia Medical Center
Gainesville, Georgia, 30501
Galesburg Clinic
Galesburg, Illinois, 61401
Galesburg Cottage Hospital
Galesburg, Illinois, 61401
InterCommunity Cancer Center of Western Illinois
Galesburg, Illinois, 61401
Medical and Surgical Specialists, LLC
Galesburg, Illinois, 61401
Comprehensive Cancer Center at Gaston Memorial
Gastonia, North Carolina, 28053
Jones Clinic
Germantown, Tennessee, 38138
Oncology Alliance, S.C. - Milwaukee - East
Glendale, Wisconsin, 53212
Charles R. Wood Cancer Center at Glens Falls Hospital
Glens Falls, New York, 12801
Wayne Memorial Hospital, Incorporated
Goldsboro, North Carolina, 27534
CCOP - Grand Rapids
Grand Rapids, Michigan, 49503
Lacks Cancer Center at Saint Mary's Mercy Medical Center
Grand Rapids, Michigan, 49503
Spectrum Health Cancer Care - Butterworth Campus
Grand Rapids, Michigan, 49503
Metropolitan Hospital
Grand Rapids, Michigan, 49506
Spectrum Health Hospital - Blodgett Campus
Grand Rapids, Michigan, 49506
Great Falls Clinic
Great Falls, Montana, 59405
Sletten Regional Cancer Institute
Great Falls, Montana, 59405
Vince Lombardi Cancer Clinic - Green Bay at Aurora BayCare Medical Center
Green Bay, Wisconsin, 54311-6519
Moses Cone Regional Cancer Center at Wesley Long Community Hospital
Greensboro, North Carolina, 27401
Leo W. Jenkins Cancer Center at Pitt County Memorial Hospital
Greenville, North Carolina, 27858
Bon Secours St. Francis Health System
Greenville, South Carolina, 29601
Greenville Hospital System Cancer Center
Greenville, South Carolina, 29605
CCOP - Greenville
Greenville, South Carolina, 29615
CCOP - Northern New Jersey
Hackensack, New Jersey, 07601
Cancer Institute of New Jersey at Hamilton
Hamilton, New Jersey, 08690
Virginia Oncology Associates - Hampton
Hampton, Virginia, 23666
PinnacleHealth Regional Cancer Center at Polyclinic Hospital
Harrisburg, Pennsylvania, 17105
Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center
Hartford, Connecticut, 06105
Hematology & Oncology Clinic
Hattiesburg, Mississippi, 34902
Hattiesburg Clinic, P.A.
Hattiesburg, Mississippi, 39401
Mason District Hospital
Havana, Illinois, 62644
Kaiser Permanente Medical Center - Hayward
Hayward, California, 94545
Pardee Memorial Hospital
Hendersonville, North Carolina, 28791
Penn State Cancer Institute at Milton S. Hershey Medical Center
Hershey, Pennsylvania, 17033-0850
Holland Community Hospital
Holland, Michigan, 49423
Memorial Cancer Institute at Memorial Regional Hospital
Hollywood, Florida, 33021
Cancer Research Center of Hawaii
Honolula, Hawaii, 96813
OnCare Hawaii, Incorporated - Lusitana
Honolulu, Hawaii, 96813
Queen's Cancer Institute at Queen's Medical Center
Honolulu, Hawaii, 96813
Straub Clinic and Hospital, Incorporated
Honolulu, Hawaii, 96813
OnCare Hawaii, Incorporated - Kuakini
Honolulu, Hawaii, 96817
St. Francis Medical Center
Honolulu, Hawaii, 96817
Kapiolani Medical Center for Women and Children
Honolulu, Hawaii, 96826
Hopedale Medical Complex
Hopedale, Illinois, 61747
Terrebonne General Medical Center
Houma, Louisiana, 70360
Marshall University Medical Center
Huntington, West Virginia, 25701
St. Mary's Medical Center
Huntington, West Virginia, 25702
Huntsville Hospital
Huntsville, Alabama, 35801
Hutchinson Area Health Care
Hutchinson, Minnesota, 55350
Holden Comprehensive Cancer Center at University of Iowa
Iowa City, Iowa, 52242
Foote Hospital
Jackson, Michigan, 49201
Baptist Cancer Institute - Jacksonville
Jacksonville, Florida, 32207
Mayo Clinic - Jacksonville
Jacksonville, Florida, 32224-9980
Joliet Oncology Hematology Associates, Limited - West
Joliet, Illinois, 60435
Freeman Cancer Institute at Freeman Health System
Joplin, Missouri, 64804
Ella Milbank Foshay Cancer Center at Jupiter Medical Center
Jupiter, Florida, 33458
West Michigan Cancer Center
Kalamazoo, Michigan, 49007
Provena St. Mary's Wasser Regional Cancer Center - Kankakee
Kankakee, Illinois, 60901
CCOP - Kansas City
Kansas City, Missouri, 64131
Cancer Center at the Good Samaritan Health Systems
Kearney, Nebraska, 68847
Kingsbury Center for Cancer Care at Cheshire Medical Center
Keene, New Hampshire, 03431
Kenton Oncology, Inc.
Kenton, Ohio, 43326
Charles F. Kettering Memorial Hospital
Kettering, Ohio, 45429
Kewanee Hospital
Kewanee, Illinois, 61443
Rappahannock General Hospital
Kilmarnock, Virginia, 22482
Cancer Center of Kansas - Kingman
Kingman, Kansas, 67068
Lenoir Memorial Cancer Center
Kinston, North Carolina, 28501
Thompson Cancer Survival Center
Knoxville, Tennessee, 37916
Baptist Hospital Of East Tennessee
Knoxville, Tennessee, 37920
Gundersen Lutheran Cancer Center at Gundersen Lutheran Medical Center
La Crosse, Wisconsin, 54601
La Grange Memorial Hospital
La Grange, Illinois, 60525
Center for Cancer Therapy at LaPorte Hospital and Health Services
La Porte, Indiana, 46350
Oncology Institute of Greater Lafayette
Lafayette, Indiana, 47904
Lakeland Regional Cancer Center at Lakeland Regional Medical Center
Lakeland, Florida, 33805
Watson Clinic
Lakeland, Florida, 33805
Haematology-Oncology Associates of Ohio and Michigan, P.C.
Lambertville, Michigan, 48144
Fairfield Medical Center
Lancaster, Ohio, 43130
Lancaster General Hospital
Lancaster, Pennsylvania, 17604
University Medical Center of Southern Nevada
Las Vegas, Nevada, 89102
CCOP - Southern Nevada Cancer Research Foundation
Las Vegas, Nevada, 89106
Gwinnett Medical Center
Lawrenceville, Georgia, 30045
Comanche County Memorial Hospital
Lawton, Oklahoma, 73505
Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, 03756
Central Pennsylvania Hematology and Medical Oncology Associates, PC
Lemoyne, Pennsylvania, 17043
Beebe Medical Center
Lewes, Delaware, 19958
Lewistown Hospital
Lewistown, Pennsylvania, 17044
Southwest Medical Center
Liberal, Kansas, 67901
St. Rita's Medical Center
Lima, Ohio, 45801
Lima Memorial Hospital
Lima, Ohio, 45804
Bryan LGH Medical Center West
Lincoln, Nebraska, 68502
Cancer Resource Center - Lincoln
Lincoln, Nebraska, 68510
St. Elizabeth Regional Medical Center
Lincoln, Nebraska, 68510
Meeker County Memorial Hospital
Litchfield, Minnesota, 55355
St. Barnabas Medical Center
Livingston, New Jersey, 07039
Sky Ridge Medical Center
Lone Tree, Colorado, 80124
Hope Cancer Care Center at Longmont United Hospital
Longmont, Colorado, 80502
Lynchburg Hematology-Oncology Clinic
Lynchburg, Virginia, 24501
McDonough District Hospital
Macomb, Illinois, 61455
Medical Center of Central Georgia
Macon, Georgia, 31208
UW Health Oncology
Madison, Wisconsin, 53715
University of Wisconsin Comprehensive Cancer Center
Madison, Wisconsin, 53792
Elliot Regional Cancer Center
Manchester, New Hampshire, 03103
Holy Family Memorial Medical Center
Manitowoc, Wisconsin, 54221
MedCentral - Mansfield Hospital
Mansfield, Ohio, 44903
St. John's Hospital
Maplewood, Minnesota, 55109
Kennestone Cancer Center at Wellstar Kennestone Hospital
Marietta, Georgia, 30060
Strecker Cancer Center at Marietta Memorial Hospital
Marietta, Ohio, 45750
Marshfield Clinic - Marshfield Center
Marshfield, Wisconsin, 54449
Northwest Ohio Oncology Center
Maumee, Ohio, 43537
St. Luke's Hospital
Maumee, Ohio, 43537
CCOP - Mount Sinai Medical Center
Miami Beach, Florida, 33140
Saint Anthony Memorial Health Centers
Michigan City, Indiana, 46360
Middlesex Hospital Cancer Center
Middletown, Connecticut, 06457
Middletown Regional Hospital
Middletown, Ohio, 45044
Medical Consultants
Milwaukee, Wisconsin, 53215
Froedtert Hospital and Medical College of Wisconcin
Milwaukee, Wisconsin, 53226-3596
Medical College of Wisconsin Cancer Center
Milwaukee, Wisconsin, 53226
Virginia Piper Cancer Institute at Abbott-Northwestern Hospital
Minneapolis, Minnesota, 55407
Hennepin County Medical Center - Minneapolis
Minneapolis, Minnesota, 55415
Veterans Affairs Medical Center - Minneapolis
Minneapolis, Minnesota, 55417
Fairview University Medical Center - University Campus
Minneapolis, Minnesota, 55455
Trinity Cancer Care Center
Minot, North Dakota, 58701
Providence Holy Cross Cancer Center
Mission Hills, California, 91346-9600
Alegent Health Community Memorial Hospital
Missouri Valley, Iowa, 51555
Trinity Medical Center - East
Moline, Illinois, 61265
Community Cancer Center of Monroe
Monroe, Michigan, 48162
Mercy Memorial Hospital System
Monroe, Michigan, 48162
Cancer Center at the Mountainside Hospital
Montclair, New Jersey, 07042
Chippewa County - Montevideo Hospital
Montevideo, Minnesota, 56265
Mary Babb Randolph Cancer Center at West Virginia University Hospitals
Morgantown, West Virginia, 26506
Carol G. Simon Cancer Center at Morristown Memorial Hospital
Morristown, New Jersey, 07962
Hackley Hospital
Muskegon, Michigan, 49443
Hematology Oncology Consultants Ltd.
Naperville, Illinois, 60540
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School
New Brunswick, New Jersey, 08903
Yale Comprehensive Cancer Center
New Haven, Connecticut, 06520-8032
Cancer Center at Medical Center of Louisiana - New Orleans
New Orleans, Louisiana, 70112
MBCCOP - LSU Health Sciences Center
New Orleans, Louisiana, 70112
Canada4 sites
Nova Scotia Cancer Centre at Queen Elizabeth II Health Sciences Centre
Halifax, Nova Scotia, B3H 1V8
Allan Blair Cancer Centre at Pasqua Hospital
Regina, Saskatchewan, S4T 7T1
University of British Columbia
Vancouver, British Columbia, V6T 1Z4
CancerCare Manitoba
Winnipeg, Manitoba, R3E 0V9
About this study
Official title: A Randomized Phase III Trial Of Interferon Alfa-2B Or Interferon Alfa-2B Plus Bevacizumab In Patients With Advanced Renal Carcinoma
RATIONALE: Biological therapies, such as interferon alfa-2b, may interfere with the growth of tumor cells. Bevacizumab may stop the growth of tumor cells by stopping blood flow to the tumor. It is not yet known whether interferon alfa-2b is more effective with or without bevacizumab in treating advanced renal cell carcinoma (kidney cancer).
PURPOSE: This randomized phase III trial is studying interferon alfa-2b and bevacizumab to see how well they work compared to interferon alfa-2b alone in treating patients with advanced renal cell carcinoma.
Read the detailed description
OBJECTIVES:
Primary
- Compare the overall survival of patients with advanced renal cell carcinoma treated with interferon alfa-2b alone or interferon alfa-2b with bevacizumab.
Secondary
- Compare the time to disease progression and objective response rates in patients treated with these regimens.
- Determine the toxicity of interferon alfa-2b in combination with bevacizumab in these patients.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to prior nephrectomy (yes vs no) and number of risk factors for disease progression (0 vs 1-2 vs 3 or more). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive interferon alfa-2b subcutaneously (SC) three times a week.
- Arm II: Patients receive interferon alfa-2b as in arm I and bevacizumab IV over 30-90 minutes on days 1 and 15.
In both arms, courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months for 2 years and then annually for up to 10 years after study entry.
PROJECTED ACCRUAL: A total of 700 patients (350 per treatment arm) will be accrued for this study within 3 years.
- Conditions
- Kidney Cancer
- Being tested
- bevacizumab, recombinant interferon alfa
- Keywords
- stage IV renal cell cancer, clear cell renal cell carcinoma, recurrent renal cell cancer
- Medical subject headings
- Kidney Neoplasms, Carcinoma, Renal Cell
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
bevacizumabBiological
10mg/kg IV infusion on Days 1 \& 15 of each cycle
recombinant interferon alfaBiological
9 million units subQ injection 3 x/week for 4 weeks
| Study group | Role | What they receive |
|---|---|---|
| Interferon | Experimental | Treatment with interferon alfa 2b Receives: Biological: recombinant interferon alfa |
| Interferon + bevacizumab | Experimental | Addition of bevacizumab to interferon alfa 2b treatment Receives: Biological: bevacizumab; Biological: recombinant interferon alfa |
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall Survival
Measured: 5 years
Secondary outcomes (2)
Time to progression
Measured: q 3 cycles
Toxicity
Measured: q cycle
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Nov 2003 (estimated)
- Study startOct 2003
- Primary completionJan 2004
- Study completionNov 2012
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (7)Papers the sponsor has linked to this study.
- Other trials for Kidney CancerStudies of the same condition, open and under way.
- More trials run by Alliance for Clinical Trials in OncologyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 732 participants (actual)
Sponsor and investigators
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute (NCI), NCIC Clinical Trials Group
- Responsible party
- Sponsor
- Investigators
- Brian I. Rini, MD, Study chair, University of California, San Francisco
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00072046
- Sponsor's protocol ID
- CALGB-90206
- Other IDs
- U10CA031946, CAN-NCIC-REC1, CDR0000335292
- Status last verified
- Jul 2016
- First submitted
- 4 Nov 2003
- Last updated
- 6 Jul 2016
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol. 2010 May 1;28(13):2137-43. doi: 10.1200/JCO.2009.26.5561. Epub 2010 Apr 5.
PubMed 20368558Rini BI, Halabi S, Rosenberg J, et al.: Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: results of overall survival for CALGB 90206. [Abstract] J Clin Oncol 27 (Suppl 15): A-LBA5019, 2009.
Rini BI, Halabi S, Rosenberg JE, et al.: CALGB 90206: a phase III trial of bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in metastatic renal cell carcinoma. [Abstract] American Society of Clinical Oncology 2008 Genitourinary Cancers Symposium, Feb 14-16, 2008, San Francisco, CA. A-350, 2008.
Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol. 2008 Nov 20;26(33):5422-8. doi: 10.1200/JCO.2008.16.9847. Epub 2008 Oct 20.
PubMed 18936475Rini BI, Halabi S, Taylor J, Small EJ, Schilsky RL; Cancer and Leukemia Group B. Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin Cancer Res. 2004 Apr 15;10(8):2584-6. doi: 10.1158/1078-0432.ccr-03-0605.
PubMed 15102658Aldin A, Besiroglu B, Adams A, Monsef I, Piechotta V, Tomlinson E, Hornbach C, Dressen N, Goldkuhle M, Maisch P, Dahm P, Heidenreich A, Skoetz N. First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2023 May 4;5(5):CD013798. doi: 10.1002/14651858.CD013798.pub2.
PubMed 37146227Nixon AB, Halabi S, Liu Y, Starr MD, Brady JC, Shterev I, Luo B, Hurwitz HI, Febbo PG, Rini BI, Beltran H, Small EJ, Morris MJ, George DJ. Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNalpha +/- Bevacizumab: Results from CALGB 90206 (Alliance). Clin Cancer Res. 2022 Jul 1;28(13):2771-2778. doi: 10.1158/1078-0432.CCR-21-2386.
PubMed 34965953
Study at a glance
From the registry record, last updated by the sponsor on 6 Jul 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized Phase III Trial Of Interferon Alfa-2B Or Interferon Alfa-2B Plus Bevacizumab In Patients With Advanced Renal Carcinoma
- ClinicalTrials.gov ID
- NCT00072046
- Acronym / sponsor ID
- CALGB-90206
- Conditions
- Kidney Cancer
- Keywords
- stage IV renal cell cancer, clear cell renal cell carcinoma, recurrent renal cell cancer
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 732 participants (actual)
- Lead sponsor
- Alliance for Clinical Trials in OncologyUniversity, hospital or other
- Collaborators
- National Cancer Institute (NCI), NCIC Clinical Trials Group
- Study start
- Oct 2003
- Primary completion
- Jan 2004 (actual)
- Study completion
- Nov 2012 (actual)
- First posted
- 6 Nov 2003 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
RATIONALE: Biological therapies, such as interferon alfa-2b, may interfere with the growth of tumor cells. Bevacizumab may stop the growth of tumor cells by stopping blood flow to the tumor. It is not yet known whether interferon alfa-2b is more effective with or without bevacizumab in treating advanced renal cell carcinoma (kidney cancer).
PURPOSE: This randomized phase III trial is studying interferon alfa-2b and bevacizumab to see how well they work compared to interferon alfa-2b alone in treating patients with advanced renal cell carcinoma.
Detailed description
OBJECTIVES:
Primary
- Compare the overall survival of patients with advanced renal cell carcinoma treated with interferon alfa-2b alone or interferon alfa-2b with bevacizumab.
Secondary
- Compare the time to disease progression and objective response rates in patients treated with these regimens.
- Determine the toxicity of interferon alfa-2b in combination with bevacizumab in these patients.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to prior nephrectomy (yes vs no) and number of risk factors for disease progression (0 vs 1-2 vs 3 or more). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive interferon alfa-2b subcutaneously (SC) three times a week.
- Arm II: Patients receive interferon alfa-2b as in arm I and bevacizumab IV over 30-90 minutes on days 1 and 15.
In both arms, courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months for 2 years and then annually for up to 10 years after study entry.
PROJECTED ACCRUAL: A total of 700 patients (350 per treatment arm) will be accrued for this study within 3 years.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Interferon | Experimental | Biological: recombinant interferon alfaTreatment with interferon alfa 2b |
| Interferon + bevacizumab | Experimental | Biological: bevacizumab, Biological: recombinant interferon alfaAddition of bevacizumab to interferon alfa 2b treatment |
Who may qualify
- Ages
- 18 to 120 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| bevacizumab10mg/kg IV infusion on Days 1 \& 15 of each cycle | Biological | Interferon + bevacizumab |
| recombinant interferon alfa9 million units subQ injection 3 x/week for 4 weeks | Biological | Interferon, Interferon + bevacizumab |
Primary outcome
Overall Survival
Time frame: 5 years
2 secondary outcomes
Time to progression
Time frame: q 3 cycles
Toxicity
Time frame: q cycle
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Jul 2016.
- Results publication: PubMed 20368558Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol. 2010 May 1;28(13):2137-43. doi: 10.1200/JCO.2009.26.5561. Epub 2010 Apr 5.
- Results publicationRini BI, Halabi S, Rosenberg J, et al.: Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: results of overall survival for CALGB 90206. [Abstract] J Clin Oncol 27 (Suppl 15): A-LBA5019, 2009.
- Results publicationRini BI, Halabi S, Rosenberg JE, et al.: CALGB 90206: a phase III trial of bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in metastatic renal cell carcinoma. [Abstract] American Society of Clinical Oncology 2008 Genitourinary Cancers Symposium, Feb 14-16, 2008, San Francisco, CA. A-350, 2008.
- Results publication: PubMed 18936475Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol. 2008 Nov 20;26(33):5422-8. doi: 10.1200/JCO.2008.16.9847. Epub 2008 Oct 20.
- Results publication: PubMed 15102658Rini BI, Halabi S, Taylor J, Small EJ, Schilsky RL; Cancer and Leukemia Group B. Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin Cancer Res. 2004 Apr 15;10(8):2584-6. doi: 10.1158/1078-0432.ccr-03-0605.
- Derived from this study: PubMed 37146227Aldin A, Besiroglu B, Adams A, Monsef I, Piechotta V, Tomlinson E, Hornbach C, Dressen N, Goldkuhle M, Maisch P, Dahm P, Heidenreich A, Skoetz N. First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2023 May 4;5(5):CD013798. doi: 10.1002/14651858.CD013798.pub2.
- Derived from this study: PubMed 34965953Nixon AB, Halabi S, Liu Y, Starr MD, Brady JC, Shterev I, Luo B, Hurwitz HI, Febbo PG, Rini BI, Beltran H, Small EJ, Morris MJ, George DJ. Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNalpha +/- Bevacizumab: Results from CALGB 90206 (Alliance). Clin Cancer Res. 2022 Jul 1;28(13):2771-2778. doi: 10.1158/1078-0432.CCR-21-2386.
Related trials for Kidney Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
Active, not recruitingPhase 3
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
Carcinoma, Renal Cell
RecruitingPhase 2/3
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma
Not yet recruitingPhase 2
Toripalimab and Lenvatinib With or Without SBRT Before Surgery for Non-Clear Cell Kidney Cancer
Nonmetastatic Locally Advanced Non-Clear Cell Renal Cell Carcinoma
Not yet recruitingPhase 1
A Study to Assess the Pharmacokinetics and Safety of Revumenib in Participants With Advanced Cancer and Hepatic or Renal Impairment
Relapsed/Refractory (R/R) Hematologic Malignancies, Acute Leukemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Brian I. Rini, MD study chair
University of California, San Francisco
493 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing bevacizumab and recombinant interferon alfa in people with Kidney Cancer, run by Alliance for Clinical Trials in Oncology at 493 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Jul 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 493 sites in United States, Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall Survival (time frame: 5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00072046, which also lists 7 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Jul 2016.